Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome unclassifiable – a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT

Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.

Article  CAS  PubMed  Google Scholar 

Baidoun F, Chen D, Patnaik M, Gangat N, Begna K, Elliott M, et al. Clinical outcome of patients diagnosed with myelodysplastic syndrome-unclassifiable (MDS-U): single center experience. Leuk Lymphoma. 2019;60:2483–7.

Article  PubMed  Google Scholar 

Margolskee E, Hasserjian RP, Hassane D, Tam W, Mathew S, Ok CY, et al. Myelodysplastic syndrome, unclassifiable (MDS-U) with 1% blasts is a distinct subgroup of MDS-U with a poor prognosis. Am J Clin Pathol. 2017;148:49–57.

Article  CAS  PubMed  Google Scholar 

Knipp S, Strupp C, Gattermann N, Hildebrandt B, Schapira M, Giagounidis A, et al. Presence of peripheral blasts in refractory anemia and refractory cytopenia with multilineage dysplasia predicts an unfavourable outcome. Leuk Res. 2008;32:33–7.

Article  PubMed  Google Scholar 

de Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, Yakoub-Agha I, et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood. 2017;129:1753–62.

Article  PubMed  PubMed Central  Google Scholar 

Garderet L, Ziagkos D, van Biezen A, Iacobelli S, Finke J, Maertens J, et al. Allogeneic stem cell transplantation for myelodysplastic syndrome patients with a 5q deletion. Biol Blood Marrow Transplant. 2018;24:507–13.

Article  PubMed  Google Scholar 

Strupp C, Nachtkamp K, Hildebrandt B, Giagounidis A, Haas R, Gattermann N, et al. New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): characteristics of refined MDS types. Leuk Res. 2017;57:78–84.

Article  PubMed  Google Scholar 

Carré M, Porcher R, Finke J, Ehninger G, Koster L, Beelen D, et al. Role of age and hematopoietic cell transplantation-specific comorbidity index in myelodysplastic patients undergoing an allotransplant: a retrospective study from the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2020;26:451–7.

Article  PubMed  Google Scholar 

Shimoni A, Robin M, Iacobelli S, Beelen D, Mufti GJ, Ciceri F, et al. Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the Chronic Malignancies Working Party of the EBMT. Br J Haematol. 2021;195:417–28.

Article  CAS  PubMed  Google Scholar 

Robin M, Porcher R, Zinke-Cerwenka W, van Biezen A, Volin L, Mufti G, et al. Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT. Bone Marrow Transplant. 2017;52:209–15.

Article  CAS  PubMed  Google Scholar 

Gagelmann N, Eikema DJ, Stelljes M, Beelen D, de Wreede L, Mufti G, et al. Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation. Haematologica. 2019;104:929–36.

Article  PubMed  PubMed Central  Google Scholar 

Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36:1703–19.

Article  PubMed  PubMed Central  Google Scholar 

留言 (0)

沒有登入
gif